Liver scanning in malignant genitourinary tumours

Area of Science:

• Urologic Oncology
• Diagnostic Imaging
• Medical Oncology

Background:

• Malignant genitourinary tumors require accurate staging to guide treatment decisions.
• Liver metastasis is a critical factor in the prognosis and management of these cancers.
• The utility of routine liver scanning for detecting early metastatic spread remains debated.

Purpose of the Study:

• To evaluate the diagnostic value of liver scanning as a routine pretreatment screening tool.
• To determine the effectiveness of liver scans in identifying metastatic disease in genitourinary cancer patients.
• To assess the impact of liver scanning on clinical decision-making prior to treatment initiation.

Main Methods:

• Retrospective review of medical records for 68 patients with malignant genitourinary tumors.
• Analysis of 74 liver scans performed as part of pretreatment screening.
• Correlation of scan results with other clinical and laboratory data for metastatic assessment.

Main Results:

• 10 out of 74 liver scans (13.5%) were positive for potential metastasis.
• A 6% false-positive rate was observed, indicating potential overdiagnosis.
• In most true-positive cases, other clinical or laboratory findings already suggested metastatic spread, limiting the scan's unique contribution.

Conclusions:

• Routine liver scanning is not a cost-effective or clinically valuable screening test for genitourinary cancer patients.
• The low yield of new information and high rate of corroborating evidence suggest that liver scans do not significantly alter pretreatment management.
• Alternative diagnostic strategies should be considered for staging liver involvement in these patients.